Mounjaro weight loss injection: List of people who qualify and how it works
The drug is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested. Mounjaro will be prescribed to severely overweight people who also suffer from a range of other health problems. It will be made by Lilly, through the NHS over the next three years.
In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity, such as type 2 diabetes, high blood pressure, heart disease and obstructive sleep apnoea.
READ MORE: New 'Frankenstein' Covid 'Stratus' strain 'soaring in UK' has one unique symptom
READ MORE: Crime boss' wife 'forced to live in a tent' when their illegal scrap yard is closed down
Dr Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today.
'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health – and greater access to weight loss drugs will make a significant difference to the lives of those people.
'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions.
'While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.'
National Institute for Health and Care Excellence (NICE) recommends tirzepatide (Mounjaro) for the management of obesity for certain patients.
Tirzepatide comes in the form of an injection which you inject yourself, once a week. Your doctor or nurse will show you how to use it.
Before prescribing tirzepatide, a healthcare professional will talk through the benefits and limitations, including any side effects you might get.
If a drug prescribed for weight loss is recommended, you will need to eat a balanced, reduced calorie diet and take part in physical activity regularly whilst taking the medicine. It is not recommended if you are pregnant or planning to get pregnant, breastfeeding, or if you have certain health conditions.
For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time.
Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.
Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription.
Health Secretary Wes Streeting said: 'Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity.
'Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best', and this Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay.
'This rollout is an important step in making these medicines more widely available, and beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming 10-year plan will deliver.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
If You Invested $10K In Omega Healthcare Investors Stock 10 Years Ago, How Much Would You Have Now?
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Omega Healthcare Investors Inc. (NYSE:OHI) is a real estate investment trust that primarily invests in skilled nursing and assisted living facilities in the U.S. and the U.K. It is set to report its Q2 2025 earnings on July 31. Wall Street analysts expect the company to post EPS of $0.75, up from $0.71 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $295.80 million, up from $252.75 million a year earlier. Don't Miss: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. . Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — The company's stock traded at approximately $34.79 per share 10 years ago. If you had invested $10,000, you could have bought roughly 287 shares. Currently, shares trade at $36.67, meaning your investment's value could have grown to $10,540 from stock price appreciation alone. However, Omega Healthcare also paid dividends during these 10 years. Omega Healthcare's dividend yield is currently 7.31%. Over the last 10 years, it has paid about $27.11 in dividends per share, which means you could have made $7,792 from dividends alone. Summing up $10,540 and $7,792, we end up with the final value of your investment, which is $18,332. This is how much you could have made if you had invested $10,000 in Omega Healthcare stock 10 years ago. This means a total return of 83.32%. However, this figure is significantly less than the S&P 500 total return for the same period, which was 256.40%. Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — Omega Healthcare has a consensus rating of "Buy" and a price target of $36.28 based on the ratings of 20 analysts. The price target implies around 1% potential downside from the current stock price. The company on May 1 announced its Q1 2025 earnings, posting FFO of $0.75, beating the consensus estimate of $0.74, while revenues of $276.80 million came in below the consensus of $288.69 million, as reported by Benzinga. "We are pleased with our first quarter results, as we continue to grow FAD per share, while further de-levering the balance sheet. We have accretively invested approximately $423 million year-to-date through April 30th and, as a result, we are increasing our 2025 AFFO guidance to be between $2.95 and $3.01 per share from our previous guidance of between $2.90 and $2.98 per share," said CEO Taylor Pickett. Check out this article by Benzinga for four analysts' insights on Omega Healthcare. Given no expected upside potential, growth-focused investors may not find Omega Healthcare stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 7.31%. Read Next: Maximize saving for your retirement and cut down on taxes: . , which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Image: Shutterstock This article If You Invested $10K In Omega Healthcare Investors Stock 10 Years Ago, How Much Would You Have Now? originally appeared on
Yahoo
3 hours ago
- Yahoo
Bereavement leave to be extended to miscarriages before 24 weeks
Parents who experience a miscarriage before 24 weeks of pregnancy will be entitled to bereavement leave under a planned law change. The government is set to amend the Employment Rights Bill to give parents the legal right to take time off work to grieve if they experience pregnancy loss at any stage. As it stands, bereavement leave is only available to parents who lose an unborn child after 24 weeks of pregnancy. Deputy Prime Minister Angela Rayner said the change will give "people time away from work to grieve". "No one who is going through the heartbreak of pregnancy loss should have to go back to work before they are ready," Rayner said. Parents are currently entitled to a fortnight's leave if they suffer pregnancy loss after 24 weeks, or if a child younger than 18 dies. The extended right to leave will be for "at least" one week, though the exact length is still being consulted on. The Employment Rights Bill, which includes further measures to protect in law the right of employees to have time off to grieve the loss of a loved one, is already making its way through Parliament. Labour MP Sarah Owen, who chairs the Women and Equalities Committee, has previously campaigned for the change. In 2021, she told MPs that after her own miscarriage she felt physically better in a few days but had "all the classic signs" of grieving. "I could not eat, I could not sleep. I really did not hold much hope that life would ever get brighter," she said. In March, business minister Justin Madders told MPs he accepted the principle of bereavement leave for pregnancy loss and promised to look at adding the right to the Employment Rights Bill. Vicki Robinson, chief executive of the Miscarriage Association, welcomed the announcement. She said it was "a hugely important step that acknowledges the often very significant impact of pre-24-week loss, not only for those experiencing the physical loss, but for their partners too". Government backs miscarriage bereavement leave Paid leave for bereaved parents is 'crucial' 'I went back after 3 days': Calls for miscarriage bereavement leave
Yahoo
3 hours ago
- Yahoo
Patients would rather see a GP than pharmacists and nurses, study finds
Patients would much rather see a GP than a pharmacist or nurse, new research suggests. A study found that people often like to see a GP and still prefer in-person appointments, considering them the 'gold standard'. The review of 33 existing studies, from the University of Southampton, also found patients often like to choose a specific doctor to maintain continuity of care. Trust and confidence decreased when patients wanted to see a GP but were directed to a nurse or other health worker instead, it added. The study noted people also wanted easier ways to book GP appointments, clearer phone options, shorter recorded messages, and simple online routes with quick responses. It comes after the Government published its 10-year health plan which intends to massively increase use of the NHS App, as well as recruit more GPs. An improved app will give patients more control over booking, moving and cancelling appointments, as well as quicker access to medics and other forms of care. The new study, published in the British Journal of General Practice, suggested confidence and trust scores appeared to be lower when people wanted a face-to-face appointment and received a call instead. The public also wanted clear details on the roles of different NHS workers, it found. Lead author Helen Atherton, professor of primary care research, said: 'Patients want a deeper connection with their doctor's practice, better communication, and the choice to see the right professional in the best way for them. 'The NHS needs to better understand what people want so it can shape its services to work for patients. 'Ignoring these fundamental needs will only exacerbate the issues it currently faces.' Writing in the journal, Prof Atherton and colleagues added: 'Patients wanted a nearby practice, with clean waiting rooms, easy appointment booking using simple systems and with short waiting times, and to be kept informed about the process.' In particular, researchers found that, for medication reviews and long-term conditions, patients preferred seeing someone they were familiar with. The research also suggested that, where a patient's condition was worsening, 69.5% of patients reported preferring to consult a GP than a pharmacist and 42.7% strongly agreed or agreed that they would prefer to consult with a GP rather than a pharmacist. Professor Kamila Hawthorne, chair of the Royal College of GPs, said: 'It's really encouraging to see how much patients value the care, and continuity of care, their GP provides – there are some things that only a GP can do for their patients, but it's also important that patients don't feel somehow short-changed if they're offered an appointment with another member of our highly-skilled multi-disciplinary team. 'Not all patients need to see a GP. Procedures such as blood tests, routine management of non-complex long-term conditions, the monitoring of repeat prescriptions, or assessment of a painful joint, for example, can be carried out by some of the various other members of the team who now work in general practice, such as nursing staff, mental health professionals, clinical pharmacists and physiotherapists. 'This also alleviates workload on GPs, allowing us to spend time with those patients with complex health needs who really do need our expert medical attention. 'However, we know that even when working as part of multi-disciplinary teams, patients often struggle to access their GP when they need to – and we share their frustrations. 'This is due to decades of under-funding of general practice and poor workforce planning, which has meant patient need for our care has escalated in recent years, while GP numbers have sadly not risen in step. 'We need thousands more GPs, and the recently published 10-Year health plan commits to providing these. 'We're now looking ahead to the revised long-term workforce plan, due later this year, to see how the Government plans to recruit more GPs and keep more GPs in the profession for longer – but also address some of the nonsensical issues GPs are reporting that they can't find appropriate employment upon qualification.' Henry Gregg, chief executive of the National Pharmacy Association, said: 'It's not surprising that people want to see a GP when they go to a GP surgery but all our research and experience shows that people are very happy to visit a pharmacy if they can access treatment or advice quickly without having to wait to see a GP. 'Pharmacists are highly trained medical professionals who offer first-class care for a range of ailments quickly and conveniently and will send patients to a GP or hospital if needs be. 'Increasingly people will be able to pop into a community pharmacy and see a highly qualitied pharmacist for things like screening, check-ups, HRT, weight management or ongoing care without lengthy waits, freeing their NHS colleagues in hospitals and GPs to do more and offering patients the choice and convenience we all want to see.' Royal College of Nursing chief nursing officer, Lynn Woolsey, said: 'Nursing staff are an integral part of any general practice delivering a range of services to patients. 'They lead public health clinics, run screening and vaccination programmes, support patients in the management of chronic disease and can diagnose and prescribe.'
